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FOOTNOTES 
 
Abbreviations used: bp, base pair; HRP, horseradish peroxidase; DMSO, dimethyl sulfoxide; ORF, 
open reading frame; PMN, polymorphonuclear neutrophil; RT-PCR, reverse transcription-
polymerase chain reaction; SNARE, soluble N-ethylmaleimeide-sensitive factor (NSF) attachment 
protein (SNAP) receptor; syt, synaptotagmin; sytdep, synaptotagmin XIV-derived protein; SDS, 
sodium dodecyl sulfate; UTR, untranslated region. 
 
* 
Corresponding author. Fax: +34 923294795. 
 E-mail address: fmollin@usal.es (F. Mollinedo). 
 
The nucleotide sequence data for human sytdep (synaptotagmin XIV-derived protein) reported in 
this work has the GenBank accession no. AY954513. 
 
 
 
   3 
 
Abstract
 
We have identified a new human gene coined sytdep (synaptotagmin XIV-derived protein) 
in human neutrophils. Sytdep encodes a 188-amino acid sequence with a 21.435 kDa deduced 
molecular mass, showing 75% identity to human synaptotagmin (syt) XIV. Human neutrophils 
express sytdep, but not syt XIV. Sytdep was upregulated during HL-60 neutrophil differentiation. 
Sytdep gene is located in human chromosome 4 and contains a unique exon, whereas syt XIV gene, 
located in chromosome 1, comprises 10 exons with 9 introns. Mouse genome did not contain 
sytdep. The N-terminal region of sytdep shows no homology with any known protein and, unlike 
synaptotagmin XIV isoforms, sytdep shows a unique C-terminal C2B domain. Polyclonal 
antibodies against the C2B domain of syt XIV recognized sytdep as a 27 kDa protein in human 
neutrophils. Genomic analyses suggest that human sytdep could derive from a retrotranslocation of 
a syt XIV transcript into chromosome 4. 
 
 
Keywords: alternative splicing, genomic characterization, gene expression, C2 domain, synaptotagmin 
XIV-derived gene, human neutrophils, cloning.  
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Introduction 
 
Synaptotagmins (syts) are a family of membrane proteins featured by an N-terminal 
transmembrane domain (type I membrane topology), two C-terminal tandem C2 domains (C2A and 
C2B), which are responsible for binding calcium and phospholipids, and a short conserved C-
terminal sequence, which may be crucial for docking to the plasma membrane and correct folding 
of the C2B domain [1-4]. Syts and SNARE [soluble N-ethylmaleimeide-sensitive factor (NSF) 
attachment protein (SNAP) receptor] proteins are likely to represent the minimal protein 
complement for Ca
2+
-triggered exocytosis [5]. In vertebrates, 16 isoforms of syt have been 
identified [6], some of which appear to function as Ca
2+
 sensors that couple Ca
2+
 to membrane 
fusion in vivo and in vitro [7, 8]. The most abundant isoform, syt I, appears to function as a Ca
2+
 
sensor that triggers the rapid exocytosis of synaptic vesicles from neurons, but the functions of the 
remaining syt isoforms are ill-defined. Syts are known to be evolutionarily and functionally well 
conserved genes and thought to be derived from common ancestral genes. Distinct variants 
generated by alternative splicing have been reported, including transmembrane  exon skipping and 
syt VII splice variants that differentially regulate synaptic vesicle recycling [9-12]. 
The partial sequence of a putative chr415 syt gene, so-called by Craxton [13], has been 
suggested to be a human orthologue of mouse syt XIV in the human genome [14]. In the present 
report, we have completed the sequence of chr415 syt gene and found by cloning, sequencing and 
chromosomal localization that this gene is different from syt XIV and encodes a novel protein that 
shows a high amino acid identity with that of syt XIV. We have coined this new gene as 
synaptotagmin XIV-derived protein (sytdep) as it is phylogenetically related to syt XIV. In addition, 
we have found that human polymorphonuclear neutrophils (PMNs) express high levels of sytdep, 
but not syt XIV. 
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Materials and methods 
 
Cell culture and neutrophil isolation. The human acute myeloid leukemia HL-60 cell line 
was grown in RPMI-1640 mediun supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 
mM glutamine, 100 units/ml penicillin, and 24 μg/ml gentamicin at 37 ºC in a humidified 
atmosphere of air/CO2 (19/1). Neutrophil differentiation of HL-60 cells was induced by adding 1.3 
% (v/v) dimethyl sulfoxide (DMSO) as previously described [15]. The human astro-
oligodendroglioma (grade II/III) GOS-3 cell line was grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 
100 units/ml penicillin, and 24 μg/ml gentamicin at 37 ºC in a humidified atmosphere of air/CO2 
(19/1). 
Neutrophils were obtained from fresh human peripheral blood by dextran sedimentation and 
centrifugation on Ficoll-Hypaque (Pharmacia LKB Biotechnology, Uppsala, Sweden), followed by 
hypotonic lysis of residual erythrocytes as previously described [16], and the final cell preparation 
contained more than 99 % neutrophils as assessed by Wright-Giemsa staining. Postnuclear 
neutrophil extracts were prepared and processed for Western blotting as previously described [17]. 
 
Nucleic acid isolation and reverse transcription-polymerase chain reaction (RT-PCR). Both 
genomic DNA and total RNA were purified from the different cell types used in this work using the 
DNAzol genomic DNA isolation reagent and the TRIZOL reagent (Gibco BRL, Gaithersburg, 
MD), respectively. RNA preparations were carefully checked by gel electrophoresis and found to be 
free of DNA contamination. Total RNA (5 μg), primed with oligo-dT, was reverse-transcribed into 
cDNA at 37ºC for 2 h using the first-strand cDNA synthesis kit (Amersham Biosciences, 
Piscataway, NJ) according to the manufacturer’s instructions in a 20-μl volume, and stored at -20ºC 
until use. A 25-μl PCR mixture contained 500 ng of cDNA template or genomic DNA, 20 pmol of 
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each primer, 0.2 mM dNTPs, 1.5 mM MgCl2 and 5 units of Taq DNA polymerase (Roche, Basel, 
Switzerland). PCR reactions were performed in a GeneAmp PCR system model 9600 (Perkin-
Elmer, Norwalk, CT). The primers used are listed in Table 1. Amplification of human β-actin 
(GenBank accession no. NM_001101)  (5’-AATATGGCACCACACCTTCTACA-3’ and 5’-
CGACGTAGCACAGCTTCTCCTTA-3’) was used as an internal and loading control. PCR 
amplification was as follows: 1 cycle at 95ºC for 5 min as an initial denaturation step, then 
denaturation at 95ºC for 30 s, annealing at 53-63ºC for 30 s, and extension at 72ºC for 90 s (30 
cycles), followed by further incubation for 15 min at 72ºC (1 cycle). PCR conditions were shown to 
be at the linear phase of amplification to assess a semiquantitative analysis. PCR products were 
electrophoresed on 2% agarose gels in 1 X TAE (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) and 
visualized by ethidium bromide staining. 
 
Cloning and sequencing. PCR products were either extracted from the agarose gel using the 
Concert
TM
 kit (Gibco BRL) or cloned into the pCR
®
2.1 vector, using the TA-TOPO cloning kit 
(Invitrogen, San Diego, CA) following the manufacturer’s indications, and sequenced in an ABI 
PRISM
®
 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). DNA sequencing was 
performed on both strands from 10 independent cDNA clones. Distinct genomic and cDNA 
sequences were aligned by ClustalW program [18]. Potential full-length cDNAs were sequenced, 
analysed, and searched against nucleotide and protein databases by using BLAST programs 
(BLASTn, tBLASTn, BLASTp). 
 
Protein biotinylation and immunoprecipitation. Cells (20 x 10
6
) were lysed with 50-200 μl 
of lysis buffer (20 mM HEPES pH 7.5, 10 mM EGTA, 40 mM -glycerophosphate, 1% NP-40, 2.5 
mM MgCl2, 2 mM orthovanadate, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 20 μg/ml 
aprotinin, 20 μg/ml leupeptin), and centrifuged at 12000 rpm for 20 min at 4ºC. Solubilized proteins 
(5-30 μg) were biotinylated with 200 μl of 10 mM Sulfo-NHS-Biotin (Sulfo-Succinimidyl-6-
   7 
(biotinamido) hexanoate; EZ-Link
TM
 Sulfo-NHS-LC-Biotin; Pierce Biotechnology, Rockford, IL) 
for 30 min at room temperature with constant rotation. Then, these biotinylated lysates were 
precleared with protein A-Sepharose as previously described [19]. Affinity-purified rabbit 
polyclonal antibody raised against the C2B domain of syt XIV fused to GST [14], and P3X63 
myeloma culture supernatant (a kind gift of Dr. F. Sánchez-Madrid, Hospital de La Princesa, 
Madrid, Spain), used as a negative control, were coupled to protein A-Sepharose beads (Amersham 
Biosciences) by incubation for 2 h at 4ºC with constant rotation. These beads were pelleted, washed 
twice with lysis buffer, and incubated with the supernatant from the preclearing step for 2 h at 4ºC 
with constant rotation. Sepharose beads were then pelleted and washed 5 times with lysis buffer. 
Then, 20 μl SDS sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, 0.1% 
bromophenol blue, 10% glycerol) were added, and samples were subjected to SDS-15% PAGE 
under reducing conditions and immunoblotted [20]. Biotynilated proteins were visualized with 
streptavidin-horseradish peroxidase (HRP) conjugate (diluted 1/1000 in TBST: Tris-buffered saline 
(TBS) -50 mM Tris-HCl pH 8.0, 150 mM NaCl- containing 0.05% Tween 20), using an ECL 
detection system (Amersham Biosciences). 
 
Results and discussion 
 
Identification and molecular characterization of sytdep 
A putative syt gene, named chr415 syt (GenBank/EMBL accession number, AJ303368), was 
identified and partially sequenced in a previous study by Craxton [13]. We cloned and sequenced 
chr415 syt in human neutrophils and found its identity to chr415 syt, with only one nucleotide 
difference (Fig. 1A). Recently, this gene was assigned to syt XIV [14] by sequence comparison. 
However, we have found evidences that questioned this assumption. First, comparison of the partial 
nucleotide and amino acid sequence of chr415 syt with that corresponding to syt XIV showed 
differences both in DNA and protein sequences (Fig. 1), although amino acid sequence comparison 
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of chr415 syt with the six isoforms of syt XIV indicated that the protein encoded by this gene 
showed a strong homology with isoform 2 of syt XIV (Fig. 1B). Secondly, we found that human 
neutrophils expressed chr415 syt, but not syt XIV (data not shown), using RT-PCR and a wide array 
of PCR primers covering the whole sequences of syt XIV and chr415 syt. On these grounds, we 
asked whether these two sequences could correspond to two different genes. Using the BLASTn 
program we analyzed the chromosome location of both genes, aligning all known syt XIV isoforms 
and chr415 syt sequence versus the full human genome. Surprisingly, two distinct gene loci for syt 
XIV and chr415 syt were found in the human chromosomal positions 1q32.2 and 4q13.2, 
respectively. 
In order to characterize the nucleotide sequences of both the genomic locus and transcript 
corresponding to the gene defined by the partial chr415 syt sequence, we carried out a BLASTn 
analysis of the partial cDNA sequence known of chr415 syt in the human chromosome 4 region 
(positions from 8932396 to 8929693), which led to a prediction of 2584 bp for the full-length 
chr415 syt cDNA (Fig. 2A). By RT-PCR assays we found a cDNA sequence that contained a single 
ORF encoding a protein of 188 amino acids with a deduced molecular mass of 21.435 kDa (Fig. 
2A). These results extended and completed the partial nucleotide sequence of chr415 syt. We also 
found one nucleotide difference at position 479, leading to a Thr-Met change at residue 97 (Fig. 
2A). We coined the name sytdep (synaptotagmin XIV-derived protein) for this new gene (GenBank 
accession no. AY954513). The predicted full-length sytdep cDNA contained a 189-bp 5’-
untranslated region (5’-UTR), a 564-bp ORF, and a 1831-bp 3’-UTR (Fig. 2A). The rather long 
length of the 3’ untranslated sequence might be similar to that highly conserved of rat and human 
syt I gene, arguing for conserved functions in non-coding regions. The sytdep cDNA showed high 
identity with three clones of human chromosome 4 (GenBank accession nos. AC096727, 
BC041902, and AJ617629). 
The amino acid sequence of human sytdep showed 75% identity to synaptotagmin XIV. The 
primary sequence of sytdep showed a 57% identity to the human syt XIV-related protein (strep14, 
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a.k.a. syt XVI), and 20-24%, 10-19% and 12% identity to other syt isoforms, syt-like proteins (slps) 
and slp homologue lacking C2 domain protein (slac2), respectively. On the other hand, the N-
terminal region (24 amino acids) of sytdep did not show any significant homology with any known 
protein domain. A physiological role for the N-terminal region of Syt in neutransmission has been 
recently reported [21]. This might suggest a specific role for sytdep that remains to be elucidated. 
Unlike most synaptotagmin XIV isoforms (Fig. 1B) that contain two C2 domains, C2A and 
C2B, sytdep contains a single C2B domain at the C-terminus, and thereby sytdep behaves as a 
single C2 domain-containing protein. C2 domains are conserved motifs of ~135 amino acids that 
often serve as Ca
2+
-binding domains [22]. The Ca
2+
-binding sites of the C2 domains are formed by 
five conserved acidic residues present in two flexible loops (loops 1 and 3) [23, 24]. However, 
sytdep as well as syt XIV [14] lack the above acidic residues, suggesting that sytdep, like syt XIV, 
is a Ca
2+
-independent C2 protein. Unlike syts that contain the conserved C-terminus WHXL motif, 
which may be crucial for docking to the plasma membrane and correct folding of the C2B domain 
[25], sytdep lacks this motif, being substituted by a WQAL motif (Fig. 1B and 2A) of uncertain 
function. 
Like other syts, sytdep protein lacks a signal peptide, and it lacks apparently a 
transmembrane domain. Sytdep contains two hydrophobic regions of approximately 8 and 16 amino 
acids (Fig. 2, A and B), which could be sufficient for a putative transmembrane domain, but the 
location of these regions in the C2B domain make this option particularly implausible as C2B 
domains do not act as transmembrane domains. Three potential N-glycosilation sites (Asn-Xaa-
Ser/Thr; 60-62, 141-143, and 158-160), one potential O-glycosilation (Thr-Xaa-Ser, 39-41) site, and 
a number of potential Ser, Thr and Tyr phosphorilation sites (12/2/2) were found in the deduced 
amino acid sequence of sytdep (Fig. 2A). No potential N-myristoylation or prenylation sites were 
detected, but three Cys residues at the N-terminal domain might be fatty-acylated as it happens in 
some syts [26]. 
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Genomic structures of human syt XIV and sytdep 
The gene structures of human syt XIV and sytdep were determined by database searching and 
PCR approaches. The human syt XIV and sytdep genes were mapped to chromosome 1 and 4, 
spanning 226,054 and 2,584 bp, respectively. Syt XIV gene consisted of 10 exons with 9 introns of 
various lengths, whereas sytdep gene showed a unique exon (Fig. 3). The Syt XIV exon 4 encoded 
the transmembrane domain, and the C2A and C2B domains were encoded by exon 7 and exons 8-
10, respectively. Syt XIV exon 3 is not translated as it occurs with other human syt genes containing 
5’ non-coding exons [13]. Six different syt XIV transcripts have been sequenced, namely: syt XIV, 
syt XIV-1, syt XIV-2, syt XIV-3, syt XIV-4, syt XIV-5 (GenBank accession nos. NM_153262, 
AJ617623, AJ617624, AJ617625, AJ617626, AJ617627), with ORFs encoding sequences of 555, 
457, 517, 265, 503 and 416 amino acids, respectively (Figs. 1B and 3). As shown in Fig. 3, we 
found that these syt XIV isoforms result from alternative splicing. In syt XIV and syt XIV-1, exon 1 
encodes the initial 4 amino acids and the first nucleotide of the 5th amino acid; exons 2 and 4 
encode 15 and 56 amino acids, respectively. In syt XIV-2 and -3, exon 4 encodes the initial 37 
amino acids, and the putative transmembrane domain is incomplete due to the fact that this exon is 
likely skipped by alternative splicing at the mRNA level. In all these syt XIV isoforms, exons 5, 6, 7 
and 8 encode 72, 92, 149 (or 64 in syt XIV-3) and 63 amino acids, respectively. So far, the initial 
amino acids of both syt XIV-4 and -5 isoforms remain unidentified, and thereby exons 5 and 6 
encode the first known 69 and 64 amino acids, respectively. The so-called syt XIV homology 
domain [14] is encoded by exon 5. Finally, exons 9 and 10 encode 27 and 103 or 102 (due to an 
amino acid deletion in syt XIV-4 and -5) amino acid residues, respectively. Thus, alternative 
splicing of the upstream sequence of transmembrane region (exons 1 and 2) and the C2A and C2B 
domains (exons 7 and 9, respectively) give rise to the distinct isoforms. Table 2 shows the distinct 
exon and intron compositions as well as the exon-intron junctions of the human syt XIV gene, 
containing the highly conserved sequences for RNA splicing in higher eukaryotes, namely GT at 
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the 5’ splice site (donor site) and AG at the 3’ splice site (acceptor site) [27], except exons 7 and 9 
that show in addition GC and TG as intron 5’- and 3’-splice donor and acceptor sites. 
 Using BLAST search from the human genome database and DNA sequencing we mapped 
sytdep locus in chromosome 4 containing the exons 1, 2, 3, 4, 8 and 10 of syt XIV with no introns 
(Fig. 3). Due to the high similarity between sytdep and syt XIV, it could be envisaged that the 
human sytdep gene might originate from a syt XIV transcript derived of chromosome 1, which was 
retrotranslocated to a genomic region of chromosome 4. Thus, as shown in Fig. 3, the sytdep 
genomic locus could result from a fusion of exons 1, 2, 3, 4, 8 and 10 of syt XIV gene. 
Interestingly, the mouse genome did not contain sytdep by database searching. In addition, 
we were unable to identify sytdep in mouse brain cDNA by RT-PCR (data not shown). Thus, the 
above putative retrotranslocation leading to sytdep apparently occurred in human, but not in mouse.     
 
Sytdep expression in human neutrophils 
Because sytdep and synaptotagmin XIV isoforms showed a high degree of homology, we 
next asked whether these genes could be differentially expressed. We designed specific primers for 
the distinct syt XIV isoforms and sytdep, and carried out RT-PCR experiments with different pairs 
of primers (Table 1 and Fig. 4), in peripheral blood human neutrophils, human leukemia HL-60 
cells, neutrophil-differentiating-HL60 cells, and human astro-oligodendroglioma GOS-3 cell line. 
The HL-60 cell line has been widely used as a cell culture model to study different molecular 
aspects of human neutrophils, as it acquires many biochemical and functional characteristics of 
mature neutrophils following treatment with DMSO for 4 days [15]. As shown in Fig. 4, sytdep was 
highly expressed in mature peripheral blood neutrophils, and resulted upregulated during neutrophil 
differentiation of HL-60 cells. However, no syt XIV expression was detected. GOS-3 cells expressed 
both sytdep and syt XIV isoform. Cloning and sequencing of the syt XIV amplified band indicated 
that this amplicon corresponded to syt XIV  isoform 2. 
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We next investigated whether the sytdep transcript was translated into protein in human 
neutrophils where we found a high sytdep mRNA expression. Due to the high identity (84%) 
between the C2B domains of syt XIV and sytdep, we assumed that a polyclonal antibody against 
the C2B domain of syt XIV could detect the C2B-containing sytdep protein. By 
immunoprecipitating biotinylated cell protein extracts with the above polyclonal antibody, we 
observed an immunoreactive band of ~27 kDa in the neutrophil extract (Fig. 5A), which could well 
correspond to the expected size of sytdep protein. The use of protein biotinylation avoided the use 
of secondary antibodies and thereby the putative interference with the 55-kDa heavy and 25-kDa 
light immunoglobulin chains. In addition, the above anti-C2B antibody recognized a band of ~27 
kDa in the postnuclear extract of human neutrophils by immunoblotting when high amounts of 
extract protein were used (Fig. 5B). This molecular mass is higher than the predicted molecular 
mass (21.435 kDa) based on the ORF of the cloned sytdep cDNA, and could be in part due to 
posttranslational modifications.  
Because we have found that SNARE proteins are involved in human neutrophil exocytosis 
[17, 19, 28], and syts have been reported to interact with SNARE proteins [5, 29-31], it is tempting 
to suggest a putative role for sytdep in the secretory response  of human neutrophils where sytdep 
mRNA is particularly highly expressed. The unique major functional domain present in sytdep is 
the C2B domain, which has been involved in binding to other C2B domains, accessory proteins 
independent of divalent cations and phospholipids, as well as in exocytosis [32-34]. The polybasic 
Lys-rich region of C2B domain has been implicated in the binding to phosphatidylinositol (4,5)-
bisphosphate in the absence of Ca
2+
 [35, 36]. On these grounds, it could be envisaged that the C2B 
domain of the new gene sytdep might be involved in membrane trafficking in human neutrophils 
via binding to phosphoinositides. The expression of sytdep in human neutrophils might increase the 
number of exocytosis-related genes, including SNARE proteins [17, 19, 28], expressed in human 
neutrophils.  
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FIGURE LEGENDS 
 
FIG. 1. Chr415 syt and syt XIV encode different proteins. (A) The nucleotide sequence of human 
polymorphonuclear neutrophil (PMN) chr415 syt  cDNA is compared with the nucleotide sequences 
of chr415 syt and syt XIV cDNAs. Human neutrophil chr415 syt cDNA was obtained by RT-PCR 
using distinct pairs of primers shown in Table 1. Dashes have been introduced to maximize 
sequence identity. Asterisks show positions in the alignment that are perfectly conserved. (B) The 
partial amino acid sequence of chr415 syt gene is compared with the complete amino acid 
sequences of the six syt XIV isoforms. The putative transmembrane region (TM) (in bold), syt XIV 
homology domain (in bold), and the C2A and C2B domains (in black boxes) are indicated. 
Asterisks indicate the Cys residues that can be fatty-acylated. ▲ indicates the Lys residues 
(polybasic region) that mediate binding to phosphoinositides. The WHXL motif (in gray boxes) is 
replaced by the WQAL motif in chr415 syt.  Arrowheads above the alignment indicate the positions 
of the alternative splicing sites. Dashes have been introduced to maximize sequence identity. Total 
number of amino acids is indicated at the end of each sequence. 
 
FIG. 2. Nucleotide and deduced amino acid sequences of human sytdep. (A) Nucleotides are 
numbered in the 5’ to 3’ direction and the predicted amino acid sequence is shown in single-letter 
code below the nucleotide sequence. Nucleotides and amino acids are numbered on the right. In-
frame termination codons are marked by ╬. The C2B domain includes from C-35 to R-188. Two 
hydrophobic regions are boxed. # indicates the Cys residues that may be fatty-acylated. A number 
of potential Ser (*), Thr (¶) and Tyr (∆) phosphorilation sites are labeled. Lys residues (▲, 
polybasic region) that can mediate binding to phosphoinositides are also indicated.  The WHXL 
motif present in syt XIV is replaced by the underlined WQAL motif. Putative polyadenylation 
signal (ATTAAA motif) are also underlined. The nucleotide and predicted amino acid sequences of 
human sytdep are available from GenBank accession no. AY954513. (B) Hydrophobicity profile of 
human sytdep. This profile was obtained according to [37] and shows two hydrophobic regions. 
 
FIG. 3. Genomic organization and transcription of the human syt XIV and sytdep genes. Exons and 
introns are represented by boxes and solid bars. Exons are numbered (1 to 10) on top of each box. 
Exons encoding the transmembrane domain (TM), the C2 domains, and the non-coding 
(untranslated) regions are represented by black, hatched, and dotted boxes, respectively. The 
number of amino acids encoded by each transcript is shown. The exon/intron boundaries are 
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indicated by arrows, and the numbers above the arrows describe position in the codon at which the 
coding sequence is separated by an intron (0 = at the codon junction; 1 and 2 = after the first codon 
and the second codon position, respectively). Broken lines indicate the corresponding exons of the 
syt XIV and sytdep genes. The numbers on top of the unique exon of sytdep indicate the exons of syt 
XIV gene locus which lead to this monoexonic gene. Chromosome location of syt XIV and sytdep 
genes are indicated in parenthesis. Letters below the exons stand for primers used in gene cloning 
from Table 1. 
 
FIG. 4. Differential expression of syt XIV and sytdep in human cells. Total RNA was purified from 
human peripheral blood neutrophils, GOS-3 cells as well as HL-60 cells and neutrophil-
differentiated HL-60 cells following  a 4-day DMSO incubation [HL-60(DMSO)]. The expression 
of sytdep and syt XIV was assessed by RT-PCR. Primers used, corresponding to those listed in 
Table 1, are shown in parenthesis. Amplification of β-actin was used as an internal control. The 
PCR products were electrophoresed and stained with ethidium bromide. The size of each amplified 
PCR fragment is shown. Data shown are representative of three separate experiments. 
 
FIG. 5. Sytdep protein in human neutrophils. (A) Biotinylated neutrophil extracts were 
immunoprecipitated with rabbit polyclonal antibody against the C2B domain of syt XIV or P3X63 
myeloma supernatant, as a negative control, and immunoprecipitates were subjected to SDS-PAGE 
and immunoblotted with streptavidin-HRP. (B) Different amounts of postnuclear extract proteins 
from resting human neutrophils were run on SDS-PAGE and analyzed by immunoblotting using the 
above anti-C2B domain antibody. The molecular mass of the immunoreactive band is indicated on 
the right. Data shown are representative of three separate experiments. 
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Table 1 
 
Primers used for sytdep and syt XIV cloning 
Primer location in the corresponding GenBank sequences of human origin are indicated. 
Type of primer Primer 
name 
Sequence  Position GenBank 
accession no. 
Gene name 
Forward A CAGTTGGTGCGGTCCATG 121342-121359 AC096727 Clone chr4 
“ “ “ 6-23 AJ617623 Syt XIV-1 
“ B CCTGATGCTGCTTCTTTTTCTC 121199-121220 AC096727 Clone chr4 
“ “ “ 125-146 NM_153262 Syt XIV 
“ “ “ 181-206 AJ617623 Syt XIV-1 
“ “ “ 288-309 AJ617624 Syt XIV-2 
“ “ “ 321-342 AJ617625 Syt XIV-3 
“ C CAGGATGACAGTGGTTCTCC 519-538 NM_153262 Syt XIV 
“ “ “ 539-558 AJ617623 Syt XIV-1 
“ “ “ 682-701 AJ617624 Syt XIV-2 
“ “ “ 715-734 AJ617625 Syt XIV-3 
“ “ “ 272-291 AJ617626 Syt XIV-4 
“ “ “ 31-50 AJ617627 Syt XIV-5 
“ D CCAGAAATTCT(C/T)ATT(A/G)GCCTGC 120999-121020 AC096727 Clone chr4 
“ “ “ 15-36 AJ303368 chr415 syt 
“ “ “ 1263-1284 NM_153262 Syt XIV 
“ “ “ 1283-1304 AJ617623 Syt XIV-1 
“ “ “ 1483-1304 AJ617624 Syt XIV-2 
“ “ “ 1188-1209 AJ617625 Syt XIV-3 
“ “ “ 1016-1037 AJ617626 Syt XIV-4 
“ “ “ 775-796 AJ617627 Syt XIV-5 
Reverse E TCATCGTGACTCTAGCAACG 120604-120624 AC096727 Clone chr4 
“ “ “ 1666-1685 NM_153262 Syt XIV 
“ “ “ 1825-1848 AJ617624 Syt XIV-2 
“ “ “ 1587-1610 AJ617625 Syt XIV-3 
“ “ “ 1493-1516 AJ617626 Syt XIV-4 
“ “ “ 1231-1254 AJ617627 Syt XIV-5 
“ F GGAGAACCACTGTCATCCTG 539-558 NM_153262 Syt XIV 
“ “ “ 682-701 AJ617624 Syt XIV-2 
“ “ “ 715-734 AJ617625 Syt XIV-3 
“ “ “ 272-291 AJ617626 Syt XIV-4 
“ “ “ 31-50 AJ617627 Syt XIV-5 
“ G TTCATCGTGACTCTAGCAACG 120603-120623 AC096727 Clone chr4 
“ “ “ 412-432 AJ303368 chr415 syt 
“ “ “ 1652-1668 NM_153262 Syt XIV 
“ “ “ 1666-1686 AJ617623 Syt XIV-1 
“ “ “ 1829-1849 AJ617624 Syt XIV-2 
“ “ “ 1591-1611 AJ617625 Syt XIV-3 
“ “ “ 1497-1517 AJ617626 Syt XIV-4 
“ “ “ 1235-1255 AJ617627 Syt XIV-5 
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Table 2 
Exon-intron junctions in the human syt XIV gene 
Exon and intron sequences are in upper and lower case letters, respectively. Start and stop codons are labeled 
in bold. The gene contains the typical gt and ag at the 5’ splice site (donor site) and 3’ splice site (acceptor 
site) for RNA splicing, required for intron removal. The variant gc and tg dinucleotides for 5’- and 3’-splice 
donor and acceptor sites are underlined. Sizes in bp of introns and exons are indicated. 
Exon Exon size (bp) Exon-intron junctions Intron   Intron size (bp) 
1 45 …….ATCATGG..........TTGAAGgtaagt 1 14431 
2 47 aatagGTGGAG……..GGAAAGgtaatt 2 297 
3 205 tcagAATCTG..........GGAAAGgtaatt 3 60374 
4 169 ctctagTATC....TTGATGCT......TTGTAAgtatcg 4 7236 
5 215 aaatagATAATT….....ATGAAGgtaaga 5 73067 
6 272 tatcagGAAACT….....CCTGAAgtaagt 6 5418 
7 450 tcttagGATATG……..CATTCTgtgagt 7 55258 
7’ 179 tcttagGATATG……..CTCATGgcaagt 7’ 55531 
8 190 ttacagGGCTGT.........CACCCAgtgagt 8 
8’ 
3509 
3488 
9 57 tgtcagATGGAC…….TCCGAGgtgagt 9 1451 
9’ 78 ttactgCTTTCC…….TCCGAGgtgagt   
10 >314 ctttagATACAT…..GAGTCATGA…   
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Figure 1A 
Herrero-Turrión, M.J. 
 
 
 
 
 
 
PMN Chr415 syt      ------------------------------------------------CCAGAAATTCTCATTAGCCTGCTTTATAATGCCACAAATGGGAGACTATCAGCAGAAGTGATAAAAGGCAGC 70 
Chr415 syt          ----------------------------------AAGACGGGTCAGTTCCAGAAATTCTCATTAGCCTGCTTTATAATGCCACAAATGGGAGACTATCAGCAGAAGTGATAAAAGGCAGC 86 
Syt XIV             TGTAGTGAAAGTACATCCTCATGTCAGTCTCTTGAACATGGCTCAGTTCCAGAAATTCTTATTGGCCTGCTTTATAATGCCACAACTGGAAGACTATCAGCAGAAGTGATAAAAGGCAGC 1320 
                                                                    *********** *** ********************* *** ****************************** 
 
PMN Chr415 syt      CACTTAAAAAATTGGGCAGCAAACAGACCACCCAATACATATGTTAAGTTAACTCTACGGAAATCCATGGATCAAGAGATGTCCAAATGCAAGATATCCATCCGCAGAGGGCGGCCAAAT 190 
Chr415 syt          CACTTAAAAAATTGGGCAGCAAACAGACCACCCAATACATATGTTAAGTTAACTCTACGGAAATCCACGGATCAAGAGATGTCCAAATGCAAGATATCCATCCGCAGAGGGCGGCCAAAT 206 
Syt XIV             CACTTCAAAAATTTGGCAGCAAACAGACCACCCAATACATATGTTAAGTTAACTCTACTGAATTCCATGGGTCAAGAGATGTCCAAATGCAAGACATCCATCCGCAGAGGGCAGCCAAAT 1440 
                    ***** ******* ******************************************** *** **** ** *********************** ***************** *******  
 
PMN Chr415 syt      CCAGTATACAAGGAAACTTTTGTTTTCAAAGTGACCCTATTTCAGCTTTCTCATGTGACACTCATGCTGTCTGTGTATAACAAAAGCAGCATGAGAAGAAA---GATGATAGGCTGGATT 307 
Chr415 syt          CCAGTATACAAGGAAACTTTTGTTTTCAAAGTGACCCTATTTCAGCTTTCTCATGTGACACTCATGCTGTCTGTGTATAACAAAAGCAGCATGAGAAGAAA---GATGATAGGCTGGATT 323 
Syt XIV             CCAGTATATAAGGAAACTTTTGTCTTTCAAGTGGCCCTATTTCAGCTTTCTGATGTGACACTCATACTGTCTGTGTATAACAAACGCAGCATGAAAAGAGAAGAGATGATAGGCTGGATT 1560 
                    ******** ************** **  ***** ***************** ************* ****************** ********* **** *   **************** 
  
PMN Chr415 syt      TATTTAGGTCTCAACAGCTCTGGAGAAGAA---CTCAATCACTGGACTGAAATGAAAGAGTCAAAAGGACGGCAAGTACGTAGATGGCAGGCGTTGCTAGAGTCACGATGAA         416 
Chr415 syt          TATTTAGGTCTCAACAGCTCTGGAGAAGAA---CTCAATCACTGGACTGAAATGAAAGAGTCAAAAGGACGGCAAGTACGTAGATGGCAGGCGTTGCTAGAGTCACGATGAA         432 
Syt XIV             TCTTTAGGTCTCAACAGCTCTGGAGAAGAAGAACTCAATCACTGGACTGAAATGAAAGAGTCAAAAGGACAGCAAGTATGTAGATGGCATGCGTTGCTAGAGTCATGA----         1668 
                    * ****************************   ************************************* ******* ********** *************** **    
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Figure 1B 
Herrero-Turrión, M.J. 
 
 
 
 
                   *      *                                 * 
SytXIV    MAIEGGERTCGVHELICIRKVSPEAVGFLSAVGVFIILMLLLFLYINKKFCFENVGGFPDLGSEYSTRKNSQDKIYNSYMDKDEHGSSSESEDEALGKYHEALSRTHNSRLPLADSRQRNYAWETRQKYSPLSAEYDGYS  
SytXIV-1  MAIEGGERTCGVHELICIRKVSPEAVGFLSAVGVFIILMLLLFLYINKKFCFENVGGFPDLGSEYSTRKNSQDKIYNSYMDKDEHGSSSESEDEALGKYHEALSRTHNSRLPLADSRQRNYAWETRQKYSPLSAEYDGYS 
SytXIV-2  --------------------------------------MLLLFLYINKKFCFENVGGFPDLGSEYSTRKNSQDKIYNSYMDKDEHGSSSESEDEALGKYHEALSRTHNSRLPLADSRQRNYAWETRQKYSPLSAEYDGYS 
SytXIV-3  --------------------------------------MLLLFLYINKKFCFENVGGFPDLGSEYSTRKNSQDKIYNSYMDKDEHGSSSESEDEALGKYHEALSRTHNSRLPLADSRQRNYAWETRQKYSPLSAEYDGYS 
SytXIV-4  ------------------------------------------------------------------------------YMDKDEHGSSSESEDEALGKYHEALSRTHNSRLPLADSRQRNYAWETRQKYSPLSAEYDGYS 
SytXIV-5  -------------------------------------------------------------------------------------------------------------------------------------------- 
 
                                                           
 
SytXIV    SEASIDEGNCIQRMRRTPPLDELQPPPYQDDSGSPHLSCTPSEIGDSKCEFSHCSNSPRCSYNKCPSEGSTGHEIESFHNKGYEEDVPSDSTAVLSPEDMSAQGSSSQLPKPFDPEPEAKYGTLDVTFDYDSQEQKLLVT 
SytXIV-1  SEASIDEGNCIQRMRRTPPLDELQPPPYQDDSGSPHLSCTPSEIGDSKCEFSHCSNSPRCSYNKCPSEGSTGHEIESFHNKGYEEDVPSDSTAVLSPEDMSAQGSSSQLPKPFDPEPEAKYGTLDVTFDYDSQEQKLLVT 
SytXIV-2  SEASIDEGNCIQRMRRTPPLDELQPPPYQDDSGSPHLSCTPSEIGDSKCEFSHCSNSPRCSYNKCPSEGSTGHEIESFHNKGYEEDVPSDSTAVLSPEDMSAQGSSSQLPKPFDPEPEAKYGTLDVTFDYDSQEQKLLVT 
SytXIV-3  SEASIDEGNCIQRMRRTPPLDELQPPPYQDDSGSPHLSCTPSEIGDSKCEFSHCSNSPRCSYNKCPSEGSTGHEIESFHNKGYEEDVPSDSTAVLSPEDMSAQGSSSQLPKPFDPEPEAKYGTLDVTFDYDSQEQKLLVT 
SytXIV-4  SEASIDEGNCIQRMRRTPPLDELQPPPYQDDSGSPHLSCTPSEIGDSKCEFSHCNNSPRCSYNKCPSEGSTGHEIESFHNKGYEEDVPSDSTAVLSPEDMSAQGSSSQLPKPFDPEPEAKYGTLDVTFDYDSQEQKLLVT 
SytXIV-5  ------------------PLDELQPPPYQDDSGSPHLSCTPSEIGDSKCEFSHCNNSPRCSYNKCPSEGSTGHEIESFHNKGYEEDVPSDSTAVLSPEDMSAQGSSSQLPKPFDPEPEAKYGTLDVTFDYDSQEQKLLVT 
 
                   
 
SytXIV    VTAVTDIPTYNRTGGNSWQVHLVLLPIKKQRAKTSIQRGPCPVFTETFKFNHVESEMIGNYAVRFRLYGVHRMKKEKIVGEKIFYLTKLNLQGKMSLPVILEPSYNHSGCDSQMSVSEMSCSESTSSCQSLEHGSVPEIL 
SytXIV-1  VTAVTDIPTYNRTGGNSWQVHLVLLPIKKQRAKTSIQRGPCPVFTETFKFNHVESEMIGNYAVRFRLYGVHRMKKEKIVGEKIFYLTKLNLQGKMSLPVILEPSYNHSGCDSQMSVSEMSCSESTSSCQSLEHGSVPEIL 
SytXIV-2  VTAVTDIPTYNRTGGNSWQVHLVLLPIKKQRAKTSIQRGPCPVFTETFKFNHVESEMIGNYAVRFRLYGVHRMKKEKIVGEKIFYLTKLNLQGKMSLPVILEPSYNHSGCDSQMSVSEMSCSESTSSCQSLEHGSVPEIL 
SytXIV-3  VTAVTDIPTYNRTGGNSWAVTPK--------------------------------------------------------------------------------------------------------------------- 
SytXIV-4  VTAVTDIPTYNRTGGNSWQVHLVLLPIKKQRAKTSIQRGPCPVFTETFKFNHVESEMIGNYAVRFRLYGVHRMKKEKIVGEKIFYLTKLNLQGKMSLPVILEPSYNHSGCDSQMSVSEMSCSESTSSCQSLEHGSVPEIL 
SytXIV-5  VTAVTDIPTYNRTGGNSWQVHLVLLPIKKQRAKTSIQRGPCPVFTETFKFNHVESEMIGNYAVRFRLYGVHRMKKEKIVGEKIFYLTKLNLQGKMSLPVILEPSYNHSGCDSQMSVSEMSCSESTSSCQSLEHGSVPEIL 
chr415 syt                                                                                                                                              DGSVPEIL 
                                                                                  
 
 
SytXIV    IGLLYNATTGRLSAEVIKGSHFKNLAANRPPN--------------------------TYVKLTLLNSMGQEMSKCKTSIRRGQPNPVYKETFVFQVALFQLSDVTLILSVYNKRSMKREEMIGWISLGLNSSGEEELNH 
SytXIV-1  IGLLYNATTGRLSAEVIKGSHFKNLAANRHPMDCSVV------------------------------------------------------------------------------------------------------- 
SytXIV-2  IGLLYNATTGRLSAEVIKGSHFKNLAANRPPN--------------------------TYVKLTLLNSMGQEMSKCKTSIRRGQPNPVYKETFVFQVALFQLSDVTLILSVYNKRSMKRKEMIGWISLGLNSSGEEELNH 
SytXIV-3  -------------------------------------------------------------------------------------------------------------------------------------------- 
SytXIV-4  IGLLYNATTGRLSAEVIKGSHFKNLAANRPPTFHPLLSDGLFCCLKHLIGGQVYIIRDTYVKLTLLN-MGQEMSKCKTSIRRGQPNPVYKETFVFQVALFQLSDVTLILSVYNKRSMKRKEMIGWISLGLNSSGEEELNH 
SytXIV-5  IGLLYNATTGRLSAEVIKGSHFKNLAANRPPTFHPLLSDGLFCCLKHLIGGQVYIIRDTYVKLTLLN-MGQEMSKCKTSIRRGQPNPVYKETFVFQVALFQLSDVTLILSVYNKRSMKRKEMIGWISLGLNSSGEEELNH 
chr415 syt          ISLLYNATNGRLSAEVIKGSHLKNWAANRPPN--------------------------TYVKLTLRKSTDQEMSKCKISIRRGRPNPVYKETFVFKVTLFQLSHVTLMLSVYNKSSMRRK-MIGWIYLGLNSSGEE-LNH 
                                                                                    ▲ ▲                                              
 
                                                                                  
SytXIV    WTEMKESKGQQVCRWHALLES- 555 
SytXIV-1  ---------------------- 457 
SytXIV-2  WTEMKESKGQQVCRWHALLES- 517 
SytXIV-3  ---------------------- 265 
SytXIV-4  WTEMKESKGQQVCRWHALLES- 503 
SytXIV-5  WTEMKESKGQQVCRWHALLES- 416 
chr415 syt          WTEMKESKGRQVRRWQALLESR 142 
  
 
 
 
C2B 
C2A 
TM 
Syt XIV 
homology domain 
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Figure 2A       
Herrero-Turrión, M.J. 
       
 
 
 
      cagttggtgcggtccatggtgagctcatcatggcgattgaaggtggagaga    51 
      gaacctgtggagtacatgaacttacctgttttagaaaagtatctccagagg   102  
      cagttgggtttttgtcagctgtttgggtgtttattatcctgatgctgcttc   153 
                                             ╬  
      tttttctctatattaataagcagttctgttttgaaaATGTTGGAGGGCTTC   204 
                                          M  L  E  G  F     5 
      CAGATCTTGGTTCAGAATACAGTACAAGGAACAATTCACAAGATAAAATGT   255 
      Q  I  L  V  Q  N  T  V  Q  G  T  I  H  K  I  K  C    22  
                                                      #   
      GTCTGTGACTCCCAAATGAGCGTGTCAGAAATGTCTTGTAGTGAAAGTACA   306 
      V  C  D  S  Q  M  S  V  S  E  M  S  C  S  E  S  T    39 
         #              *              *  # 
      TCCGCATGTCAGTCTCTCGAAGACGGGTCAGTTCCAGAAATTCTCATTAGC   357 
      S  A  C  Q  S  L  E  D  G  S  V  P  E  I  L  I  S    56 
                  *              * 
      CTGCTTTATAATGCCACAAATGGGAGACTATCAGCAGAAGTGATAAAAGGC   408 
      L  L  Y  N  A  T  N  G  R  L  S  A  E  V  I  K  G    73 
                                    * 
      AGCCACTTAAAAAATTGGGCAGCAAACAGACCACCCAATACATATGTTAAG   459 
      S  H  L  K  N  W  A  A  N  R  P  P  N  T  Y  V  K    90 
                                             ¶  Δ               
      TTAACTCTACGGAAATCCATGGATCAAGAGATGTCCAAATGCAAGATATCC   510 
      L  T  L  R  K  S  M  D  Q  E  M  S  K  C  K  I  S   107 
         ¶           *                 *  ▲     ▲     * 
      ATCCGCAGAGGGCGGCCAAATCCAGTATACAAGGAAACTTTTGTTTTCAAA   561 
      I  R  R  G  R  P  N  P  V  Y  K  E  T  F  V  F  K   124 
                                 Δ  
      GTGACCCTATTTCAGCTTTCTCATGTGACACTCATGCTGTCTGTGTATAAC   612 
      V  T  L  F  Q  L  S  H  V  T  L  M  L  S  V  Y  N   141 
 
      AAAAGCAGCATGAGAAGAAAGATGATAGGCTGGATTTATTTAGGTCTCAAC   663 
      K  S  S  M  R  R  K  M  I  G  W  I  Y  L  G  L  N   158 
            * 
      AGCTCTGGAGAAGAACTCAATCACTGGACTGAAATGAAAGAGTCAAAAGGA   714 
      S  S  G  E  E  L  N  H  W  T  E  M  K  E  S  K  G   175 
      *  *                                      * 
      CGGCAAGTACGTAGATGGCAGGCGTTGCTAGAGTCACGATGAatacaataa   765 
      R  Q  V  R  R  W  Q  A  L  L  E  S  R  ╬            188 
      gcaaacagttaccatccaatgcagcatatttctaattacaacattactgtt   816 
      tctaccaagtcgccattggaagagctgttctttgaagaatcatattcaacc   867 
      ttttaccaaaatgctttaagttctatggaaagaacatctaatactgagata   918 
      aatgaagaaaatatgtgtatctgatagagcttgtttgggaaactgagaaac   969 
      gtacattatcattgttaaactaacagtcctccagaaatttaataagatgtt  1020 
      tttgatttgaagttaattttaatttagcaaaagagccggtaattttatgaa  1071 
      aaatcaaaattataagtgattttaaaaaccagagttttagtcgcaatataa  1122 
      ttttaatatcactctacatattatttataaaacatagtttggccagtccct  1173 
      ggtgtttgtaatgttctttaatatgaaaaagtagtcctccaaccctatcgt  1224 
      aagtcatatctaatggcgaagggtttcagtcacattgaaaattgttttatt  1275 
      tcagacatgttccttttgtgcacttagtttcattgtgcctcagttcctctc  1326 
      tatagcactaaatctaagtgcagacaagcattcgttttcatacaggaatgt  1377 
      ttttaatatgcaaagtcactgtgctggtcccttgcaagtctttagacaggt  1428 
      tgtactgtagaactacgtaactttctgttgaaagcacttcctgtattcttg  1479 
      tatttcaatgtaggaagctagtagagcaagactttactttaaaatttcttt  1530 
      cagtgattgactcttcaaaaattgcagtaatgtgaaaatacattttttttt  1581 
      acaaactgaaaacacagcagataagctgtagaaaatgaaaaacgattcaat  1632  
      tttaattttctgctctgagtatttagtaaccaacactgcctaaagcaggta  1683 
      gcatccaaaataagaaactattctctctctaaatcttcactcttacttcaa  1734 
      tttacatttgtgatataaagactatgcagttctcagtttaaatcggaacat  1785 
      catgttaaaaacagttctgagattccttacgaagtttccaataacttgtga  1836 
      ctagactttatgaaatttacggataaagttcttcaacatgatgttatcttg  1887 
      tgcctttcatgtaagttgaatttgctcatacggcttgaaagttgtatttgc  1938 
      aaaattaagccttcgatttttataaatgcaacgattcctcagaacagtgtc  1989 
      gcaagatctttatttcctccgaagtatgtaaaagttgtatgatgtgctaat  2040 
      tttgtaaatggcaagtcactttcatttgtttttatatttagaaactctaat  2091 
      taatcaggaatattataagctgttttctttataattttgcttcttacctaa  2142 
      tgtatcattttatgcatatactttattaaatagagtatgttttatatatat  2193 
      taaaaatagtttcttttttctccttctcatttctagttcaaatagacaaaa  2244 
      acatactatttaccagttactaaaaagcagtatatcattgctcctagtccc  2295 
      aaaaaagtactatatattattataaactagaacttgttattaccataataa  2346 
      aaaaagaccgtgaaattctgtattttttcatttaaaaatggcagctctatg  2397 
      cattcatacacatgaattataagaaaaaatacaaaaggtatattggatgac  2448 
      atgaggtttgagaatgtgttttacagggctgcattaaagggaaaaattcat  2499 
      attttattgttacatcaatgagctttctccaggatttttacaataaacgag  2550 
      taggaattagaacctgaatcaaatggcgagagat                   2584 
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Figure 2B 
Herrero-Turrión, M.J. 
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Figure 3 
Herrero-Turrión, M.J. 
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Figure 4 
Herrero-Turrión, M.J. 
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Figure 5 
Herrero-Turrión, M.J. 
 
 
 
 
 
 
 
 
 
